Zacks Research Lowers Earnings Estimates for DENTSPLY SIRONA

DENTSPLY SIRONA Inc. (NASDAQ:XRAY) – Research analysts at Zacks Research lowered their Q3 2026 EPS estimates for DENTSPLY SIRONA in a report released on Thursday, August 27th. Zacks Research analyst Team now expects that the medical instruments supplier will post earnings per share of $0.31 for the quarter, down from their previous forecast of $0.37. The consensus estimate for DENTSPLY SIRONA’s current full-year earnings is $1.41 per share. Zacks Research also issued estimates for DENTSPLY SIRONA’s Q4 2026 earnings at $0.40 EPS, FY2026 earnings at $1.50 EPS, Q2 2027 earnings at $0.38 EPS, Q3 2027 earnings at $0.41 EPS, Q4 2027 earnings at $0.39 EPS, FY2027 earnings at $1.50 EPS, Q1 2028 earnings at $0.35 EPS, Q2 2028 earnings at $0.41 EPS and FY2028 earnings at $1.64 EPS.

A number of other brokerages also recently commented on XRAY. Weiss Ratings reiterated a “sell (e+)” rating on shares of DENTSPLY SIRONA in a research note on Monday, August 3rd. Mizuho cut their price target on DENTSPLY SIRONA from $16.00 to $14.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 6th. Piper Sandler lifted their price target on DENTSPLY SIRONA from $13.00 to $14.00 and gave the stock a “neutral” rating in a report on Wednesday, July 29th. Barclays upped their price objective on DENTSPLY SIRONA from $9.00 to $11.00 and gave the stock an “underweight” rating in a research report on Monday. Finally, BMO Capital Markets reissued a “market perform” rating and set a $13.00 target price on shares of DENTSPLY SIRONA in a research report on Friday, August 7th. Three research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat, DENTSPLY SIRONA presently has an average rating of “Hold” and a consensus target price of $13.54.

DENTSPLY SIRONA Price Performance

Shares of XRAY opened at $11.04 on Friday. DENTSPLY SIRONA has a twelve month low of $9.40 and a twelve month high of $14.86. The firm’s fifty day simple moving average is $12.08 and its 200-day simple moving average is $11.75. The firm has a market capitalization of $2.20 billion, a price-to-earnings ratio of -4.01, a PEG ratio of 1.38 and a beta of 0.85. The company has a current ratio of 1.63, a quick ratio of 1.07 and a debt-to-equity ratio of 1.48.

DENTSPLY SIRONA (NASDAQ:XRAY) last issued its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $0.52 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.35 by $0.17. DENTSPLY SIRONA had a negative net margin of 14.99% and a positive return on equity of 20.84%. The company had revenue of $898.00 million during the quarter, compared to the consensus estimate of $889.93 million. During the same quarter in the previous year, the firm earned $0.52 earnings per share. The firm’s quarterly revenue was down 4.1% on a year-over-year basis. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS.

Institutional Trading of DENTSPLY SIRONA

Several institutional investors and hedge funds have recently made changes to their positions in XRAY. BlackRock Inc. acquired a new stake in shares of DENTSPLY SIRONA in the 2nd quarter valued at about $283,405,000. First Eagle Investment Management LLC increased its position in DENTSPLY SIRONA by 3.2% during the fourth quarter. First Eagle Investment Management LLC now owns 14,640,555 shares of the medical instruments supplier’s stock worth $167,342,000 after buying an additional 458,744 shares during the period. AQR Capital Management LLC increased its position in DENTSPLY SIRONA by 109.8% during the second quarter. AQR Capital Management LLC now owns 13,316,771 shares of the medical instruments supplier’s stock worth $211,470,000 after buying an additional 6,970,086 shares during the period. Lazard Asset Management LLC lifted its stake in DENTSPLY SIRONA by 0.9% in the third quarter. Lazard Asset Management LLC now owns 10,200,525 shares of the medical instruments supplier’s stock valued at $129,445,000 after buying an additional 92,868 shares during the last quarter. Finally, Southpoint Capital Advisors LP acquired a new stake in shares of DENTSPLY SIRONA in the first quarter valued at approximately $116,000,000. 95.70% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at DENTSPLY SIRONA

In related news, Director Brian P. Mckeon purchased 10,000 shares of the business’s stock in a transaction that occurred on Friday, June 12th. The shares were purchased at an average cost of $10.12 per share, for a total transaction of $101,200.00. Following the purchase, the director directly owned 10,000 shares of the company’s stock, valued at $101,200. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Brian T. Gladden purchased 9,985 shares of DENTSPLY SIRONA stock in a transaction that occurred on Monday, June 15th. The stock was bought at an average cost of $10.02 per share, with a total value of $100,049.70. Following the completion of the transaction, the director owned 61,849 shares of the company’s stock, valued at $619,726.98. The trade was a 19.25% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have purchased 35,160 shares of company stock valued at $351,179 in the last ninety days. Insiders own 0.46% of the company’s stock.

DENTSPLY SIRONA Company Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.